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Dealing Drugs with the Bush
RACHEL A. ANKENY
The past year in bioethics in Australia has been relatively predictable. We
continue to struggle with rising healthcare costs, though thankfully not on par
with numerous other countries due to a relatively positive economic outlook.
We are still fighting difficulties associated with higher medical indemnity costs,
which have again caused many physicians to leave private practice, particu-
larly in high-risk and specialty practice areas. In response, the federal govern-
ment (following a shuffle of ministerial positions including that of the federal
health minister) delayed the imposition of the medical indemnity levy for
physicians until mid 2005.1 In May, the Australian Law Reform Commission
and the Australian Health Ethics Commission issued their final joint report on
genetic testing entitled “Essentially Yours” 2 and endorsed use of genetic tests
by insurance companies, despite the concerns of some geneticists and many
members of the public about their scientific reliability.3 However, they also
advocated the establishment of the Human Genetics Commission of Australia
(HGCA) to oversee such uses of genetic tests in terms of both scientific and
actuarial reliability, and debates continue over the implementation of this and
a number of their other recommendations. And state governments continue to
phase in smoking bans in public places, with most implementing full bans in
enclosed restaurants and cafes and planning to require provision of nonsmok-
ing areas in all pubs within the next year.
But perhaps the most intriguing development of the year was the economic
assault on Australian health by the United States, not well covered even in
the Australian media except as an occasional aside in longer discussions
on U.S.-Aussie relations. In this case, the target is control over the costs of
pharmaceuticals as provided under Australia’s Pharmaceutical Benefits Scheme
(PBS), which is part of the public health insurance system. The U.S. pharma-
ceutical industry was relatively successful in defeating price controls over
prescription drugs in the United States during 2003, and legislation recently
passed by Congress as part of the Medicare prescription drug benefit package
specifically prohibits the government from attempting to negotiate lower drug
prices. So now they have turned their sights on Australia, with assistance from
the Bush administration under the auspices of an ongoing free-trade negotia-
tion.4 Ultimately, this negotiation is an attack on the public health insurance
system that delivers decent care to all Australians, for roughly half what
Americans pay under their private system (in terms of percentage GDP) but
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on a par with what other developed countries with public health insurance
schemes pay.
The PBS has operated in some form in Australia for over 50 years, evolving
from a service to provide a limited number of “lifesaving and disease-
preventing drugs” free of charge to the community, into a broader subsidized
scheme around 1960 for access to generic drugs available in different forms and
marketed under different brand names.5 The PBS in its current form was
established in part to achieve the objective of “securing a reliable supply of
pharmaceutical products at the most reasonable cost to Australian taxpayers
and consumers.” 6 It involves a system of regulated prices and per-unit subsi-
dies on many prescription medicines (2,500 in total are currently on the
formulary). The maximum cost for a pharmaceutical benefit item on the PBS is
currently AU$23.10 for general patients and $3.70 for concessional patients
(e.g., pensioners, disabled and unemployed persons); nearly 80% of the total
expenditure goes toward prescriptions for concession card holders.7 On aver-
age for every dollar people spend out of pocket at the chemist on PBS-
subsidized medicines, the government contributes $5. In 2001–2002, the total
subsidy amounted to 0.6% of GDP and 15% of total federal health expenditure.8
Predictions are that this system is unsustainable in its current form for several
reasons: increasing costs (due to new, increasingly more expensive drugs being
listed), overprescribing, leakage (drugs with more than one indication having
differential cost-benefit ratios; see below for more detail), consumer demands,
an aging population, and, not least of all, aggressive marketing by the phar-
maceutical industry.
To be listed on the PBS in Australia, a drug must be assessed for its safety,
quality, and efficacy by a committee under the auspices of the Therapeutic
Goods Administration (TGA), and application must then be made to the
Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the PBS.
Applications are generally made by pharmaceutical companies but can also be
put forward by professional medical bodies, health professionals, private indi-
viduals, and their representatives. The PBAC assesses the evidence for the
drug’s effectiveness, including its cost-effectiveness, and makes a recommen-
dation to the Minister for Health and Ageing as to whether the drug should be
listed. If the Minister accepts the recommendation, the drug is then referred to
a pricing authority that negotiates with manufacturers on the price at which the
drug will be listed. This process establishes whether the drug is cost-effective —
that is, “whether at the agreed price it yields an additional unit of health
benefit at less cost than the next best alternative drug.” 9 There is also negoti-
ation over how much of the additional net health benefit that would be created
by regulating the drug via the PBS should be transferred back to the pharma-
ceutical firm via the agreed price paid by the patient (as discussed earlier, some
“leakage” can occur here if the drug has more than one indication, or a
different indication emerges later). Of course, pharmaceutical companies that
produce drugs in the same therapeutic class compete with each other to maxi-
mize these tradeoffs.
As persuasively argued by Sydney economist Donald Wright, there are
options available to pharmaceutical companies outside the PBS —that is, they
can choose not to invest in the process of applying to the PBAC and engaging
in the bargaining process, if the amount they will receive should the drug
become PBS-listed would not produce a profit. In fact, Wright shows (using a
Rachel A. Ankeny
242
Nash bargaining model) that a regulated pharmaceutical firm (one whose drug
goes through the PBS negotiation process) is unambiguously better off than it
would be in an unregulated environment. Even though the agreed price
between the government and the pharmaceutical company for a PBS-listed
drug is less than for the same drug on the “open market,” the total profit is a
function also of the quantity of the drug sold at the regulated price, which is
considerably more than would be sold at an unregulated, or non-PBS subsi-
dized, price, particularly in a competitive drug class.10
By way of comparison, consider other countries with universal eligibility for
public pharmaceutical subsidies within public health insurance schemes, such
as Sweden, France, Spain, New Zealand, and the United Kingdom. Manufac-
turer prices for top-selling pharmaceuticals in Australia are similar in pricing to
France, Spain, and New Zealand, although prices are around 50% higher in
Sweden and the United Kingdom. For new pharmaceuticals, the gap is even
less, with similar prices in all of these comparison countries except the United
Kingdom, where the price is 54% higher. On the other hand, prices for
top-selling drugs in the United States are at least 162% higher (and still 84%
higher when discounts are taken into account) than in Australia, and 104%
higher on new or innovative drugs considered alone.11 Clearly, there is a gap,
but in which system, and along which sociopolitical as well as economic axis?
Against this historical and economic backdrop, the multinational pharmaceu-
tical companies approached the U.S. Congress in 2003. In retrospect, we
Australians received subtle warning cues from our government about antici-
pated threats to the system around mid 2003, in the form of enhanced public
education campaigns about PBS and its structure, and new labeling that details
the full cost of drugs, not just the patient contribution. The recent U.S.
Medicare reform bill explicitly requires further examination of “free trade” and
competition within the international pharmaceutical market12 and, according to
the New York Times, “requires the Bush administration to apprise Congress on
progress toward opening Australia’s drug pricing system” 13 as part of a more
general challenge being mounted against foreign government “price controls,”
notably those used in Canada. This negotiation is part of a broader one with
Australia over agricultural exports and imports of other types of American
goods.14
Although the attempts by big pharma to bring Australian prices more in line
with those of the United States are understandable in terms of propping up
their bottom line, they are not defensible ethically. Spokespersons for various
pharmaceutical companies have claimed that the negotiations are justified
because other countries do not pay for their “share” of pharmaceutical research,15
but adequate evidence has not been presented to support this claim, particu-
larly for developed countries such as Australia that do have large federally
funded medical research programs (and commit monies to some types of
innovative research that are less strongly supported in the United States —for
instance, in reproductive technologies and stem cell therapies). If such a gap
indeed exists in terms of contributions to development and research of phar-
maceuticals in relation to population, per capita income, and so on, the
Australian system already allows pharmaceutical companies to negotiate their
prices accordingly or choose instead to offer their products to consumers
outside the PBS, as many (often more expensive) drugs are currently supplied.
Ethical questions may be raised if access to the most appropriate drug for a
Dealing Drugs with the Bush
243
particular patient or disease condition becomes wholly unavailable through the
PBS and economically unaffordable out of pocket, but so far the system has
worked quite well.
Australia is playing the big pharma game, negotiating rather effectively to
further its ideals of providing high-quality healthcare for all at reasonable
prices in a relatively efficient manner, though admittedly the system sometimes
falls short as might be expected. As of early February 2004, an agreed text for
the Australia–United States Free Trade Agreement had been formulated. Aus-
tralian negotiators have stated publicly that they do not consider the PBS to be
negotiable: “The Government remains committed to ensuring access to afford-
able medicines through a sustainable PBS, and negotiation of an FTA with the
U.S. will not compromise these commitments.”16 Perhaps the bottom line was
best summarized by Mark Vaile, the Australian Minister for Trade, when he
was quoted as saying, “It is different in Australia. We are a differently struc-
tured society.” 17 And at least when it comes to our PBS and our public health
insurance system, we’d like to keep it that way.
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